SITC Press Releases

Oncology News Burst from the FDA: FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-cell Precursor Acute lymphoblastic leukemia

By SITC Communications posted 20 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39th Annual Meeting

By Thomas Martin posted 30 days ago
The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39 th Annual Meeting The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC’s upcoming 39 th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, ...
0 comments

Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 39th Annual Meeting

By Thomas Martin posted 10-31-2024
Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 39 th Annual Meeting MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA) . The abstracts will be presented at SITC’s upcoming 39 th Annual Meeting & Pre-Conference Programs taking place November 6–10, 2024, in Houston, ...
0 comments

Oncology News Burst from the FDA: FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer

By SITC Communications posted 10-07-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

By SITC Communications posted 09-19-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

By SITC Communications posted 09-16-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships

By SITC Communications posted 08-19-2024
In its mission to make “cure” a reality for cancer patients everywhere and support the development of early career investigators, the Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of its 2024 fellowships totaling $640,000. “With the generous support of our industry partners, SITC is able to back the promising research of early career investigators and future leaders in cancer immunotherapy,” said SITC President Leisha A. Emens, MD, PhD. “This investment in our field's future aims to develop new immunotherapy strategies and improve patient outcomes.” ...
0 comments

Oncology News Burst from the FDA: FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable Non-small Cell Lung Cancer

By SITC Communications posted 08-19-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Announces 2024 Class of Fellows to the Academy of Immuno-Oncology

By SITC Communications posted 08-06-2024
The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO) . The luminaries of the 2024 class will be inducted at an event during SITC’s 39th Annual Meeting & Pre-Conference Programs , taking place November 6–10, 2024 in Houston, TX. “Each year, we honor those who have made seminal contributions to move the field of cancer immunotherapy forward to the benefit of patients,” said SITC President Leisha A. Emens, MD, PhD. “SITC is proud to welcome this slate of incredible individuals to the 2024 class and is excited to honor them ...
0 comments

Oncology News Burst from the FDA: FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy

By SITC Communications posted 08-05-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma

By SITC Communications posted 08-02-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

By SITC Communications posted 07-31-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Society for Immunotherapy of Cancer Announces Annual Award Recipients

By SITC Communications posted 07-22-2024
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) honors notable contributors to the cancer immunotherapy field each year. SITC is thrilled to announce its 2024 Annual Awards recipients who will be honored at its 39 th Annual Meeting & Pre-Conference Programs , taking place November 6–10, 2024 in Houston, TX. “The Annual Awards celebrate individuals whose significant contributions directly benefit patients and advance the field of immuno-oncology,” said SITC President Leisha A. Emens, MD, PhD. “SITC is honored to acknowledge these exceptional members of our ...
0 comments

SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy

By SITC Communications posted 06-24-2024
MILWAUKEE – A new manuscript series – The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer – outlines the current state of the immunotherapy field, elevates the most pressing challenges and proposes the promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. The first manuscript of the series, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ,” is available now in the Journal for ImmunoTherapy of Cancer ( JITC ). This ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma

By SITC Communications posted 06-18-2024
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments